【CSCO 2022 Prospect】IMpower010 research leads the reform of adjuvant therapy for early-stage non-small cell lung cancer

Lung cancer is one of
the most life-threatening malignancies in a population.
In recent years, the incidence of lung cancer has shown signs of increasing significantly in most countries, with non-small cell lung cancer (NSCLC) accounting for about 85%.

Most early NSCLC can be surgically removed, however, more than 50% of patients will relapse or metastasize
within 5 years after surgery.
At present, postoperative adjuvant chemotherapy is the standard of care for patients with early-stage NSCLC, but adjuvant chemotherapy only improves the 5-year survival rate by 5%.

Based on the fact that immunotherapy can improve the body's immune microenvironment and have a "long tailing" effect, it suggests that the sooner immunotherapy is applied, the better
the efficacy.
Early stage patients have better immune function, and immunotherapy is expected to bring better results
.
The results of a number of early clinical trials also indicate the potential
of immunotherapy in the perioperative treatment of early lung cancer.

IMpower010 is a randomized, multicenter, open-label Phase III clinical study conducted in 227 centers in 22 countries and regions, enrolling patients aged 18 years or older, ECOG score 0-1, complete tumor resection IB (≥4 cm) to stage IIIA NSCLC (AJCC version 7), postoperative 1-4 cycles of cisplatin-based chemotherapy, 1005 patients who meet the requirements are pressed 1 :1 Randomized to receive 16 cycles of atezolizumab (1200 mg every 3 weeks) or BSC, aiming to compare the efficacy and safety
of atezolizumab with optimal supportive care.

The IMpower010 study is the first randomized phase III clinical study
to demonstrate that adjuvant immunotherapy in early resectable NSCLC significantly improves disease-free survival.
Adjuvant immunotherapy reduced the risk of tumor recurrence or death by 34% in 1% of patients with stage II-IIIA NSCLC with PD-L≥1 and 21
% in all patients with stage II-IIIA NSCLC compared with the best supportive care group.

In the recent plenary session of the World Congress on Lung Cancer (WCLC) 2022, the IMpower010 study updated the latest OS data
.
The results of the study showed that as of April 18, 2022 (median follow-up of 45.
3 months), atezolizumab adjuvant immunotherapy compared with best supportive care (BSC) prolonged overall survival
in patients with stage II-IIIA NSCLC by ≥1% of patients with PD-L1 TC.
This data update also adds a strong evidence-based basis
for atezolizumab as a postoperative adjuvant immunotherapy for NSCLC.

As an international study, several centers in China are also involved in the
study.
The upcoming 25th National Clinical Oncology Congress and 2022 CSCO Annual Meeting, Professor Wang Jie, the main domestic investigator of IMpower010 research and Cancer Hospital of the Chinese Academy of Medical Sciences, is specially invited to deeply interpret the IMpower010 research data and look forward to the application prospect
of immunotherapy in the early perioperative period of NSCLC.

Resources:

https://mp.
weixin.
qq.
com/s/rMMwwWM11BjsYQepbvLTbw

https://mp.
weixin.
qq.
com/s/qLkauU7mzOmsKyBfksP0PQ

https://mp.
weixin.
qq.
com/s/rtFWKGyPRMul3esBdtMB4g

https://mp.
weixin.
qq.
com/s/BoSflrYF_qQCa8u3shoOwA